UPDATE TO THE LONG-TERM EFFICACY AND SAFETY OF IPTACOPAN IN C3 GLOMERULOPATHY: 39-MONTH PHASE 2 EXTENSION STUDY DATA

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/8855b732932db8adc152d154650cc7cd.pdf
UPDATE TO THE LONG-TERM EFFICACY AND SAFETY OF IPTACOPAN IN C3 GLOMERULOPATHY: 39-MONTH PHASE 2 EXTENSION STUDY DATA

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Carla
Nester
Carla Nester carla-nester@uiowa.edu University of Iowa Stead Family Children’s Hospital Iowa City United States *
Ute Eisenberger ute.eisenberger@uk-essen.de University Hospital, University of Duisburg-Essen Department of Nephrology Essen Germany -
Alexandre Karras alexandre.karras@aphp.fr Hôpital Européen Georges Pompidou Service de Néphrologie Paris France -
Moglie Le Quintrec m-lequintrec-donnette@chu-montpellier.fr Centre Hospitalier Universitaire de Montpellier Service de Néphrologie et Transplantation Rénale Montpellier France -
Liz Lightstone l.lightstone@imperial.ac.uk Imperial College London Centre for Inflammatory Disease, Department of Immunology and Inflammation London United Kingdom -
Manuel Praga mpragat@senefro.org Complutense University Department of Medicine Madrid Spain -
Giuseppe Remuzzi giuseppe.remuzzi@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri IRCCS Bergamo Italy -
Maria José Soler mariajose.soler@vallhebron.cat Hospital Universitari Vall d’Hebron Nephrology Department Barcelona Spain -
Junhao Liu junhao-1.liu@novartis.com Novartis Pharmaceuticals Corporation Global Drug Development East Hanover United States -
Rubeen Israni rubeen.israni@novartis.com Novartis Pharmaceuticals Corporation Global Drug Development East Hanover United States -
Jean Grisouard jean-1.grisouard@novartis.com Novartis Pharma AG Global Drug Development Basel Switzerland -
Induja Krishnan induja.krishnan@novartis.com Novartis Pharmaceuticals Corporation Global Drug Development East Hanover United States -
Edwin Wong edwin.wong1@nhs.net Royal Victoria Infirmary National Renal Complement Therapeutics Centre Newcastle United Kingdom -
-
-